In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OrbusNeich: Tissue Engineering Meets Coronary Stents

Executive Summary

While most companies are developing new ways to deliver drugs off of stents, OrbusNeich is looking to capture circulating endothelial progenitor cells onto its device to promote healing naturally, without drugs.
Advertisement

Related Content

EuroPCR Highlights: TAVI Set to Continue Rampant Growth
Next-Generation Coronary Stent Start-Ups: Making a Difference in a Mature Market
The Future of Drug-Eluting Stents Part I: Novel Next-Generation Designs
Nexeon MedSystems Inc.
Stent Recap: Turmoil in 2007--What's Ahead for Interventional Cardiology?
Behind the DES Debate: A New Model for Device Development?
Industry Perspective - The Medtech Industry: A Look Back at 2006
TCT Highlights: Late Stent Thrombosis Controversy Continues
Edwards: Battling the Innovator's Dilemma
Edwards: Will a Biotech Deal Strategy Work For a Device Company?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel